Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized placebo-controlled trial of F61 in moderate COVID-19 patients at high risk of progression
ChiCTR2300067426Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of F61 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Proportion of subjects who became severe or above within 8 days of randomization. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
F61
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2300067426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067426.